Anti-glycated CD59 antibodies and uses thereof
AssigneePresident and Fellows of Harvard College
InventorJose Halperin
Life of this patent
Estimating the term…
Abstract
The invention includes antibodies or antigen-binding fragments thereof which bind specifically to glycated CD59, compositions containing one or a combination of such antibodies or antigen-binding fragments thereof, hybridoma cell lines that produce the antibodies, and methods of producing and using the antibodies or antigen-binding fragments thereof for diagnosis and treatment of diabetic conditions and diabetic-associated conditions.
Claims44
An isolated antibody or antigen-binding fragment thereof, that binds specifically to a glycated epitope of glycated CD59, wherein the epitope includes a glycated lysine.
A nucleic acid sequence that encodes the antibody clone 7.
A hybridoma that produces the antibody clone 7.
An expression vector comprising an isolated nucleic acid molecule encoding antibody clone 7 or an antigen-binding fragment thereof.
An isolated antibody or an antigen-binding fragment thereof which specifically binds glycated CD59, wherein the antibody or the antigen-binding fragment thereof competitively inhibits the binding of clone 7 to glycated CD59.
A kit comprising a package comprising a container containing an expression vector comprising an isolated nucleic acid molecule encoding antibody clone 7 or an antigen-binding fragment thereof.
An immunogenic polypeptide, wherein
- 1) the polypeptide comprises the amino acid sequence set forth as WKFEH (SEQ ID NO:2), and
- 2) the amino acid sequence of the polypeptide is a modified amino acid sequence of SEQ ID NO:5 or fragment thereof wherein the modification of the amino acid sequence set forth as SEQ ID NO:5 is the presence of one or more glucocytol-lysine residues, or the replacement of one or more cysteine residues with alanine residues, or the addition of a cysteine residue to the C-terminus, or combinations thereof.
Dependencies are inferred from the claim text.